What Makes Glaukos (GKOS) a Good Investment?

Core Insights - Alger Weatherbie Specialized Fund focuses on investing in a portfolio of 50 small and mid-cap companies with promising growth potential [1] - The US equity market ended Q4 2025 positively, with the S&P increasing by 2.7%, driven by better-than-expected corporate earnings and a supportive macroeconomic environment [1] - The fund's Class A shares underperformed the Russell 2500 Growth Index in Q4 2025, with Real Estate and Consumer Staples contributing positively while Information Technology and Health Care sectors detracted from performance [1] Company Highlights - Glaukos Corporation (NYSE:GKOS) is highlighted as a key stock, focusing on novel therapies for glaucoma and other eye disorders [2][3] - Glaukos experienced a one-month return of -7.131% but a 52-week gain of 22.99%, with a market capitalization of $7.131 billion as of January 21, 2026 [2] - The company reported a revenue growth of approximately 37% year-over-year, driven by its flagship glaucoma product, iDose, and received FDA approval for its next-generation corneal health product, Epioxa, which is expected to drive further growth [3]